secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001171843-24-002826
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Q1 net loss narrows to $3.8M; $5.8M PIPE to fund MiNK-215 IND in 2025
--------------------------------------------------------------------------

- Net loss of $3.8M ($0.11 per share) vs $5.7M ($0.17) YoY; cash used in ops $2.5M.
- Quarter-end cash $5.8M; closed $5.8M PIPE at 25% premium with new investor.
- Phase 2 trial of agenT-797 in gastroesophageal cancers actively enrolling; initial results expected H2 2024.
- MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models (AACR data).
- Upcoming ATS presentation (May 21) on agenT-797 in severe respiratory distress in a renal transplant patient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/0001171843-24-002826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/f8k_051424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer